Results 11 to 20 of about 88,672,115 (295)

Clinical landscape of LAG-3-targeted therapy [PDF]

Immuno-Oncology and Technology, 2022
Lymphocyte-activated gene 3 (LAG-3) is a cell surface inhibitory receptor and a key regulator of immune homeostasis with multiple biological activities related to T-cell functions.
L. Chocarro, E. Blanco, H. Arasanz, L. Fernández-Rubio, A. Bocanegra, M. Echaide, M. Garnica, P. Ramos, G. Fernández-Hinojal, R. Vera, G. Kochan, D. Escors   +11 more
doaj   +8 more sources

Understanding LAG-3 Signaling [PDF]

International Journal of Molecular Sciences, 2021
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in immunity and emerged some time ago as an inhibitory immune checkpoint molecule comparable to PD-1 and CTLA-4 and a potential target for enhancing anti-cancer ...
Luisa Chocarro, Ester Blanco, Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Leticia Fernández-Rubio, Pilar Morente, Gonzalo Fernández-Hinojal, Miriam Echaide, Maider Garnica, Pablo Ramos, Ruth Vera, Grazyna Kochan, David Escors   +13 more
openaire   +5 more sources

LAG-3 expression in the inflammatory microenvironment of glioma [PDF]

Journal of Neuro-Oncology, 2021
Abstract Purpose Immune modulatory therapies including immune checkpoint inhibitors have so far failed to result in clinically meaningful efficacy in glioma. We aimed to investigate lymphocyte activation gene 3 (LAG-3), an inhibitory receptor on immune cells and target of second-generation immune checkpoint inhibitors ...
Maximilian J. Mair, Barbara Kiesel, Katharina Feldmann, Georg Widhalm, Karin Dieckmann, Adelheid Wöhrer, Leonhard Müllauer, Matthias Preusser, Anna S. Berghoff   +8 more
openaire   +3 more sources

LAG-3 Role in Infection

The 1st International Electronic Conference on Molecular Sciences: Druggable Targets of Emerging Infectious Diseases, 2021
Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple biological activities over T cell activation and effector functions [1,2,3].
Luisa Chocarro, Ester Blanco, Hugo Arasanz, Ana Bocanegra, Leticia Fernández-Rubio, Miriam Echaide, Maider Garnica, Pablo Ramos, Grazyna Kochan, David Escors   +9 more
openaire   +2 more sources

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies

OncoImmunology, 2023
Lymphocyte-activation gene-3 (LAG-3), an immune checkpoint receptor, negatively regulates T-cell function and facilitates immune escape of tumors. Dual inhibition of LAG-3 and programmed cell death receptor-1 (PD-1) significantly improved progression ...
Tuba N. Gide, Elizabeth C. Paver, Zarwa Yaseen, Nigel Maher, Nurudeen Adegoke, Alexander M. Menzies, Ines Pires da Silva, James S. Wilmott, Georgina V. Long, Richard A. Scolyer   +9 more
doaj   +2 more sources

Development of a LAG-3 immunohistochemistry assay for melanoma [PDF]

Journal of Clinical Pathology, 2022
Aims A robust immunohistochemistry (IHC) assay was developed to detect lymphocyte-activation gene 3 (LAG-3) expression by immune cells (ICs) in tumour tissues. LAG-3 is an immuno-oncology target with demonstrable clinical benefit, and there is a need for a standardised, well-characterised assay to measure its ...
Lori Johnson, Bryan McCune, Darren Locke, Cyrus Hedvat, John B. Wojcik, Caitlin Schroyer, Jim Yan, Krystal Johnson, Angela Sanders-Cliette, Sujana Samala, Lloye M. Dillon, Steven Anderson, Jeffrey Shuster   +12 more
openaire   +2 more sources

LAG-3 Expression Predicts Outcome in Stage II Colon Cancer [PDF]

, 2021
Introduction: LAG-3 is an inhibitory immune checkpoint molecule that suppresses T cell activation and inflammatory cytokine secretion. T cell density in the tumor microenvironment of colon cancer plays an important role in the host’s immunosurveillance ...
Gaëlle Rhyner Agocs, José A. Galván, Zlobec, Inti, Alessandro Lugli, Naziheh Assarzadegan, Richard Kirsch, Heather Dawson, Inti Zlobec, Martin D. Berger, Rhyner Agocs, Gaëlle, Lugli, Alessandro, Dawson, Heather, Galván, José A., Kirsch, Richard, Berger, Martin D., Assarzadegan, Naziheh   +15 more
core   +2 more sources

Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment

OncoImmunology, 2020
The immune checkpoint blockade (ICB) immunotherapy has prolonged overall survival for cancer patients but the response rates are low. The resistance to ICB is likely due to compensatory upregulation of additional immune inhibitory molecules.
Min Yang, Wenwen Du, Lixian Yi, Shaoxian Wu, Chunyan He, Wensi Zhai, Cuihua Yue, Runzi Sun, Ashley V. Menk, Greg M. Delgoffe, Jingting Jiang, Binfeng Lu   +11 more
doaj   +1 more source

Adaptive and Innate Immune Cells in Fetal Human Cytomegalovirus-Infected Brains

Microorganisms, 2020
Background: The understanding of the pathogenesis of cytomegalovirus (CMV)-induced fetal brain lesions is limited. We aimed to quantify adaptive and innate immune cells and CMV-infected cells in fetal brains with various degrees of brain damage. Methods:
Yann Sellier, Florence Marliot, Bettina Bessières, Julien Stirnemann, Ferechte Encha-Razavi, Tiffany Guilleminot, Nacilla Haicheur, Franck Pages, Yves Ville, Marianne Leruez-Ville   +9 more
doaj   +1 more source

Proximity Between LAG-3 and the T Cell Receptor Guides Suppression of T Cell Activation and Autoimmunity [PDF]

Cell
Du J, Chen H, You J, Hu W, Liu J, Lu Q, Zhang Y, Gao J, Lin MJ, Foster CJR, Rao E, Cammer M, Yin W, Koide S, Lu CP, Chen W, Lou J, Wang J.   +17 more
exaly   +2 more sources